King's College London

Research portal

Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome

Research output: Contribution to journalArticle

Carla M. Startin, Sarah Hamburg, Rosalyn Hithersay, Kin Y. Mok, John Hardy, Tamara Al-Janabi, The LonDownS Consortium, Andre Strydom

Original languageEnglish
Pages (from-to)245-257
JournalAlzheimers & Dementia
Issue number2
Early online date28 Nov 2018
Accepted/In press10 Sep 2018
E-pub ahead of print28 Nov 2018


King's Authors



Down syndrome (DS) is associated with an almost universal development of Alzheimer's disease. Individuals with DS are therefore an important population for randomized controlled trials to prevent or delay cognitive decline, though it is essential to understand the time course of early cognitive changes.


We conducted the largest cognitive study to date with 312 adults with DS to assess age-related and Alzheimer's disease–related cognitive changes during progression from preclinical to prodromal dementia, and prodromal to clinical dementia.


Changes in memory and attention measures were most sensitive to early decline. Resulting sample size calculations for randomized controlled trials to detect significant treatment effects to delay decline were modest.


Our findings address uncertainties around the development of randomized controlled trials to delay cognitive decline in DS. Such trials are essential to reduce the high burden of dementia in people with DS and could serve as proof-of-principle trials for some drug targets.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454